Proud to announce that OptiLight Intense Pulse Light (IPL) by Lumenis is FDA approved for managing dry eye and MGD.
The Lumenis multi-center, double-blinded, randomized controlled FDA trial showed that OptiLight Intense Pulse Light (IPL) significantly improved tear breakup time, meibum quality, and meibomian gland expressibility. The clinical trial joins a long list of over 40 peer-reviewed studies of Lumenis’ IPL with OPT that have shown the same results, as well as reduction of inflammatory markers.
Some of the benefits of the OptiLight Intense Pulse Light (IPL) include unique sqaure wave multi-pulse technology (better patient experience), increase of mitochondrial activity within glands, photo-biomodulation and oil gland upregulation, photo-sanitizing to reduce overgrowth of bacteria and demodex mites, decreases inflammation in treated areas (ie eyelids and whites of the eye), strengthen the collagen in the skin (anti-agining properties), and is very well accepted 5 minute in-office treatment.
To learn more about OptiLight Intense Pulse Light (IPL), please schedule an appointment today.